Antibody Information
General Information of This Antibody
| Antibody ID | ANI0ZCCGA |
|||||
|---|---|---|---|---|---|---|
| Antibody Name | HuBa-1-3D |
|||||
| Synonyms |
a humanized IgG1 antibody against human DLK-1
Click to Show/Hide
|
|||||
| Antigen Name | Protein delta homolog 1 (DLK1) |
Antigen Info | ||||
| Click to Show/Hide the Sequence Information of This Antibody | ||||||
Each Antibody-drug Conjugate Related to This Antibody
Full Information of The Activity Data of The ADC(s) Related to This Antibody
ADCT-701 [Phase 1 (discontinued)]
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Patients Enrolled |
Eligible participants must have histologically confirmed neuroendocrine neoplasms or adrenocortical carcinoma (ACC) with measurable disease (RECIST 1.1), prior standard therapy failure, ECOG ≤2, and adequate organ function. Exclusions include recent anticancer treatments (within 4 weeks), active infections, uncontrolled autoimmune diseases, QTcF ≥480 ms, pregnancy, or live vaccines within 30 days. Contraception is required during and post-treatment (9.5 months for females, 6.5 months for males).
Click to Show/Hide
|
||||
| Administration Dosage |
ADCT-701 in 2microgram/kg-255microgram/kg (weight based dosing), IV over 30 minutes (+15 minutes)
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT06041516 | Clinical Status | PHASE1 | ||
| Clinical Description |
A First-in-Human Phase I Trial With Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors and Carcinomas
|
||||
| Primary Endpoint |
The study aims to determine the maximum tolerated dose (MTD) of ADCT-701 by assessing dose-limiting toxicities (DLTs) during Cycle 1 (Days 1-21), with adverse events (AEs) categorized by type and severity grade.
|
||||
| Other Endpoint |
Safety evaluations include monitoring AEs through 30 days post-treatment, while efficacy is assessed via overall response rate (ORR), duration of response (DOR), progression-free survival (PFS), and overall survival (OS) over 5 years. Pharmacokinetic (PK) analysis measures PBD-conjugated antibody, total antibody, and unconjugated warhead SG3199 for up to 2 years, alongside immunogenicity testing for anti-drug antibodies (ADAs).
Click to Show/Hide
|
||||